Abstract | BACKGROUND: CASE REPORT: A female Asian nonsmoker with adenocarcinoma was given gefitinib as first-line treatment with significant efficacy. However, after approximately 1.5 years, progression occurred. She then received chemotherapy ( pemetrexed/ carboplatin) until progression, followed by treatment with gefitinib to which the patient responded a second time. After progression, treatment with chemotherapy ( docetaxel/ cisplatin) was instituted and again followed by gefitinib. A recent positron emission tomography/computed tomography (PET/CT) scan showed complete remission under gefitinib. CONCLUSIONS: This case report indicates that resistance to gefitinib in NSCLC can be reversed after chemotherapy. Thus, re-exposure to gefitinib may be justified in selected cases.
|
Authors | Xiao-Dong Li, Yi-Ting Geng, Chang-Ping Wu, Hua Shen, Jing Sun, Yong-Qian Shu, Yong-Mei Yin |
Journal | Onkologie
(Onkologie)
Vol. 33
Issue 8-9
Pg. 466-9
( 2010)
ISSN: 1423-0240 [Electronic] Switzerland |
PMID | 20838064
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 S. Karger AG, Basel. |
Chemical References |
- Antineoplastic Agents
- Quinazolines
- Gefitinib
|
Topics |
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, secondary)
- Drug Resistance, Neoplasm
(drug effects)
- Female
- Gefitinib
- Humans
- Lung Neoplasms
(drug therapy, secondary)
- Middle Aged
- Quinazolines
(administration & dosage)
- Treatment Outcome
|